UNSPSC 51371901: Acetylmethadol or methadyl acetate

This classification denotes an opioid receptor agonist with the molecular formula C23H31NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L59OC40KWJ, chemically known as 6-(dimethylamino)-4,4-diphenyl-3-heptanol acetate (ester) but generally known as acetylmethadol, which bears US NIH Compound Identifier 10517. Acetylmethadol comes in forms base and hydrochloride. European Medicines Agency schedules Acetylmethadol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05232MIG.

UNSPSC 51371901 Acetylmethadol or methadyl acetate is a Commodity code that does not align with the recent state and local opportunities tagged under it. The three most recent solicitations — from Seminole County, Florida; the Texas Health and Human Services Commission; and the Minnesota Multistate Cooperative Purchasing Alliance — all concern naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products. None of these opportunities addresses acetylmethadol or methadyl acetate specifically. The code shows little relevant recent activity, and the opportunities posted suggest a data-tagging mismatch rather than active demand for the acetylmethadol commodity itself.

The geographic spread of the three posted opportunities spans Florida, Texas, and Minnesota, with the Minnesota procurement operating through a multistate cooperative purchasing vehicle serving multiple jurisdictions including Oregon. The issuing bodies include a county health department (Seminole County), a state health agency (Texas HHS Commission), and a multistate cooperative purchasing alliance administered by a state procurement office. The most recent opportunity is Seminole County's IFB 60459723LAS, posted June 30, 2026, with a response deadline of July 26, 2023 (note the date discrepancy in the source), which solicits 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries. The MMCAP generic pharmaceuticals RFP (S1070000015802) closed March 26, 2026, and the Texas HHS RFI (HHS0017013) was posted April 3, 2026, as a preliminary market-intelligence tool preceding a formal solicitation. Vendors pursuing this code should verify the correct UNSPSC classification with issuing bodies before investing proposal resources.